Leerink Bumps PT on Exelixis (EXEL) Up to $16 Following Latest Cabozantinib Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Upgrades Exelixis (EXEL) to Overweight
October 10, 2016 9:09 AM EDTPiper Jaffray upgraded Exelixis (NASDAQ: EXEL) from Neutral to Overweight.
For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.
Shares of Exelixis closed at $12.95 yesterday.
... MoreExelixis (EXEL) Bullish View Reiterated at Leerink Following Positive CABOSUN Data
October 10, 2016 7:40 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and $15 price target on Exelixis (NASDAQ: EXEL) after the company reported positive CABOSUN data to be presented as a late breaker at ESMO later today.
Schmidt commented, "Overall, the data looks clearly statistically... More
Exelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCC
October 10, 2016 6:16 AM EDTExelixis, Inc. (Nasdaq: EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Principal investigator Toni K. Choueiri, M.D. will present detailed data from late-breaking CABOSUN abstract [#LBA30_PR] today in the Presidential Symposium 3 session, starting at 16:30 CEST (local Copenhagen time) / 10:30 a.m. EDT / 7:30 a.m. PDT at the European Society for Medical Oncology (ESMO) 2016, which is being held October 7 11, 2016 in Copenhagen.
CABOSUN... More
